Association between vitamin D supplementation and chronic pain scores: evidence from cancer survivors
Published
June 26, 2025
Paper ID
PAP-000035
Status
Published
DOI
10.65712/tmj.test000293
Advance Services
Abstract
Background: chronic pain scores remains a leading cause of avoidable harm among cancer survivors. Methods: Eligible participants were cancer survivors. Results: Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. Conclusion: Future work should test vitamin D supplementation in a pragmatic multicentre trial.
Introduction
The cost of chronic pain scores to health systems is substantial. chronic pain scores remains a leading cause of avoidable harm among cancer survivors.
Practice around vitamin D supplementation varies widely between centres. The cost of chronic pain scores to health systems is substantial. Earlier studies of vitamin D supplementation were small or single-centre. chronic pain scores remains a leading cause of avoidable harm among cancer survivors.
Discussion
These findings suggest that vitamin D supplementation is associated with better chronic pain scores in cancer survivors. Future work should test vitamin D supplementation in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. These findings suggest that vitamin D supplementation is associated with better chronic pain scores in cancer survivors.
Implementation will depend on staffing, cost and local protocols.
Strengths include the sample size and blinded outcome assessment. These findings suggest that vitamin D supplementation is associated with better chronic pain scores in cancer survivors.
Conclusions
Vitamin D supplementation should be considered for cancer survivors to improve chronic pain scores.
References
1. Kaur M, Andersen L, et al. Tranexamic acid and post-operative delirium. Lancet. 2019;73(7):319-1525.
2. Larsen K, Novak R, et al. Delayed cord clamping and acute kidney injury. Diabetes Care. 2014;336(5):604-1610.
3. Larsen G, Moreau P, et al. Prone positioning and surgical site infection. Lancet. 2015;365(6):408-1386.
4. Volkov H, Herrera N, et al. An antibiotic stewardship programme and ventilator-free days. Eur Heart J. 2025;194(12):587-1760.
5. Kaur P, Tanaka K, et al. Low-dose aspirin and length of stay. Pediatrics. 2016;315(12):301-1146.
6. Farouk Q, Lindqvist M, et al. Machine-learning triage and ventilator-free days. BMJ. 2023;193(2):236-1472.
7. Volkov T, Novak I, et al. An enhanced recovery pathway and chronic pain scores. BMJ. 2010;275(11):847-975.
8. Moreau U, Larsen T, et al. High-flow nasal oxygen and length of stay. JAMA. 2024;186(7):557-1093.
Appendices
Ethics approval: IRB-6581.
Materials and Methods
The primary outcome was chronic pain scores, assessed blind to allocation. Eligible participants were cancer survivors.
Analyses were adjusted for age, sex and baseline severity.
Missing data were handled with multiple imputation. The primary outcome was chronic pain scores, assessed blind to allocation. We conducted a multicentre observational study across 7 centres between 2014 and 2022. Eligible participants were cancer survivors.
Results
The adjusted odds ratio was 0.65 (95% CI 0.43 to 0.62). The adjusted odds ratio was 0.45 (95% CI 0.45 to 0.81). Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Centre B | 143 | 4 | 39.3 | 0.96 |
| Centre B | 297 | 5 | 39.1 | 0.93 |
| Centre B | 516 | 14 | 23.7 | 0.62 |
| Male | 362 | 117 | 19.9 | 0.77 |
| Age ≥ 65 | 478 | 3 | 35.9 | 0.74 |
| Female | 279 | 116 | 23.5 | 0.99 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.68 (95% CI 0.29 to 0.79). chronic pain scores occurred in 20% of the intervention group versus 28% of controls. Serious adverse events were rare and similar between groups.